logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9073947 B1

PDFFull Text
Date of Patent:
Jul. 07, 2015

Filed:

Jun. 10, 2012

Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity

Applicants:

Brian L. Hodous, Cambridge, MA (US);

Lesley Liu-bujalski, Bedford, MA (US);

Reinaldo Jones, Lowell, MA (US);

Donald Bankston, Dracut, MA (US);

Theresa L. Johnson, Salem, MA (US);

Igor Mochalkin, San Diego, CA (US);

Ngan Nguyen, Somerville, MA (US);

Hui Qiu, Acton, MA (US);

Andreas Goutopoulos, Boston, MA (US);

Nadia Brugger, Cambridge, MA (US);

Inventors:

Brian L. Hodous, Cambridge, MA (US);

Lesley Liu-Bujalski, Bedford, MA (US);

Reinaldo Jones, Lowell, MA (US);

Donald Bankston, Dracut, MA (US);

Theresa L. Johnson, Salem, MA (US);

Igor Mochalkin, San Diego, CA (US);

Ngan Nguyen, Somerville, MA (US);

Hui Qiu, Acton, MA (US);

Andreas Goutopoulos, Boston, MA (US);

Nadia Brugger, Cambridge, MA (US);

Assignee:

Merck Patent GmbH, Darmstadt, DE;

Attorneys:

Dwight D. Kim

EMD Serono Research and Development Institute

Primary Examiner:

Golam M M Shameem

Int. Cl.
CPC ...
A61K 31/506 (2006.01); C07D 401/12 (2006.01); C07F 5/02 (2006.01); C07D 213/68 (2006.01); C07D 213/73 (2006.01); C07D 213/74 (2006.01); C07D 239/47 (2006.01); C07D 239/48 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 495/04 (2006.01); C07D 405/14 (2006.01); C07D 451/02 (2006.01); C07D 471/10 (2006.01);
U.S. Cl.
CPC ...
C07F 5/022 (2013.01); C07D 213/68 (2013.01); C07D 213/73 (2013.01); C07D 213/74 (2013.01); C07D 239/47 (2013.01); C07D 239/48 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 495/04 (2013.01); C07D 405/14 (2013.01); C07D 451/02 (2013.01); C07D 471/10 (2013.01);
Abstract

The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.

Find Patent Forward Citations

Loading…